Overexpression of macrophage migration inhibitory factor induces angiogenesis in human breast cancer.

Macrophage migration inhibitory factor (MIF) is known to be an important contributor to tumor progression. Overexpression of MIF has been reported in different types of tumors. However, the correlation between MIF expression and tumor pathologic features in patients with breast cancer has not been elucidated. In this study, we examined the expression of MIF, vascular endothelial growth factor (VEGF) and interleukin-8 (IL-8) in human tissues with or without tumor. In addition, we investigated the expression of MIF in MDA-MB-231, MCF-7 (breast cancer cell lines) and MCF-10A (epithelial cell line) cells, and its effect on VEGF and IL-8. We found that MIF was overexpressed in breast cancer tissues compared with normal ones. The level of MIF showed the positive correlation between the expression of IL-8 and tumor microvessel density (MVD). The patients with positive MIF expression in tumor tissues showed a significantly worse disease-free survival compared with negative ones. Increased MIF serum levels were also found to correlate with higher levels of IL-8 in the sera of the patients with breast cancer. In vitro experiments successfully detected MIF in breast cell lines. However, the expression level of it by normal epithelial cells was much less than that of cancer cells. Exogenous MIF did not cause endothelial tube formation and migration but induced a dose dependent increase in VEGF and IL-8 secretion in breast cancer cell lines. In summary, our studies show that human breast cancer tissue expresses MIF. Its in vitro effect on VEGF and IL-8 indicates that MIF may contribute to tumor in angiogenesis and thus play an important role in the pathogenesis of breast cancer.

[1]  J. Bernhagen,et al.  Crystal structure at 2.6-A resolution of human macrophage migration inhibitory factor. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[2]  M. Suzuki,et al.  High expression of macrophage migration inhibitory factor in human melanoma cells and its role in tumor cell growth and angiogenesis. , 1999, Biochemical and biophysical research communications.

[3]  H. Moses,et al.  Stromal fibroblasts in cancer initiation and progression , 2004, Nature.

[4]  John David,et al.  Macrophage migration inhibitory factor (MIF) sustains macrophage proinflammatory function by inhibiting p53: Regulatory role in the innate immune response , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[5]  Xin Huang,et al.  Macrophage Migration Inhibitory Factor Stimulates Angiogenic Factor Expression and Correlates With Differentiation and Lymph Node Status in Patients With Esophageal Squamous Cell Carcinoma , 2005, Annals of surgery.

[6]  E. Dahl,et al.  Macrophage migration inhibitory factor (MIF) promotes cell survival by activation of the Akt pathway and role for CSN5/JAB1 in the control of autocrine MIF activity , 2007, Oncogene.

[7]  K. Iczkowski,et al.  Further evidence for increased macrophage migration inhibitory factor expression in prostate cancer , 2005, BMC Cancer.

[8]  T. H. van der Kwast,et al.  High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. , 2001, Cancer research.

[9]  Y. Hishikawa,et al.  Overexpression of macrophage migration inhibitory factor induces angiogenesis and deteriorates prognosis after radical resection for hepatocellular carcinoma , 2005, Cancer.

[10]  R. Atkins,et al.  Macrophage migration inhibitory factor expression in human renal allograft rejection. , 1998, Transplantation.

[11]  K. Xie,et al.  Interleukin-8 and human cancer biology. , 2001, Cytokine & growth factor reviews.

[12]  P. Carmeliet,et al.  Angiogenesis in cancer and other diseases , 2000, Nature.

[13]  Yuji Sato,et al.  Macrophage Migration Inhibitory Factor (MIF) , 1996 .

[14]  Inhibition of tumor growth and metastasis in vitro and in vivo by targeting macrophage migration inhibitory factor in human neuroblastoma , 2006, Oncogene.

[15]  M. Burdick,et al.  Cancer CXC chemokine networks and tumour angiogenesis. , 2006, European journal of cancer.

[16]  J. Folkman,et al.  The role of angiogenesis in tumor growth. , 1992, Seminars in cancer biology.

[17]  Y. Yang,et al.  Identification of macrophage migration inhibitory factor as a potent endothelial cell growth-promoting agent released by ectopic human endometrial cells. , 2000, The Journal of clinical endocrinology and metabolism.

[18]  R. Jain,et al.  Irradiation of a primary tumor, unlike surgical removal, enhances angiogenesis suppression at a distal site: potential role of host-tumor interaction. , 2000, Cancer research.

[19]  M. Iannettoni,et al.  Macrophage migration inhibitory factor and CXC chemokine expression in non-small cell lung cancer: role in angiogenesis and prognosis. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[20]  Ravikumar Aalinkeel,et al.  Gene Expression of Angiogenic Factors Correlates with Metastatic Potential of Prostate Cancer Cells , 2004, Cancer Research.

[21]  J. Folkman,et al.  Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma. , 1991, The New England journal of medicine.

[22]  P. Woll,et al.  Interleukin-8/CXCL8 is a growth factor for human lung cancer cells , 2004, British Journal of Cancer.

[23]  R. Bucala,et al.  An Essential Role for Macrophage Migration Inhibitory Factor (MIF) in Angiogenesis and the Growth of a Murine Lymphoma , 1999, Molecular medicine.

[24]  F. Bozza,et al.  MACROPHAGE MIGRATION INHIBITORY FACTOR LEVELS CORRELATE WITH FATAL OUTCOME IN SEPSIS , 2004, Shock.

[25]  S. Fan,et al.  Clinical implications of circulating angiogenic factors in cancer patients. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  J. Kononen,et al.  Tissue microarrays for high-throughput molecular profiling of tumor specimens , 1998, Nature Medicine.

[27]  N. Funata,et al.  Expression of Macrophage Migration Inhibitory Factor in Human Breast Cancer: Association with Nodal Spread , 2002, Japanese journal of cancer research : Gann.

[28]  Yuji Sato,et al.  Involvement of Macrophage Migration Inhibitory Factor (MIF) in the Mechanism of Tumor Cell Growth , 1998, Molecular medicine.

[29]  Yan Ding,et al.  Increased epithelial and serum expression of macrophage migration inhibitory factor (MIF) in gastric cancer: potential role of MIF in gastric carcinogenesis , 2006, Gut.

[30]  Shiyong Li,et al.  Identification of interleukin‐8 as estrogen receptor‐regulated factor involved in breast cancer invasion and angiogenesis by protein arrays , 2004, International journal of cancer.

[31]  L. Ellis,et al.  The implications of angiogenesis for the biology and therapy of cancer metastasis , 1994, Cell.

[32]  Michael Bacher,et al.  Macrophage migration inhibitory factor: Roles in regulating tumor cell migration and expression of angiogenic factors in hepatocellular carcinoma , 2003, International journal of cancer.

[33]  J. Foidart,et al.  Macrophage migration inhibitory factor (MIF) expression in human glioblastomas correlates with vascular endothelial growth factor (VEGF) expression , 2002, Neuropathology and applied neurobiology.

[34]  G. Hannon,et al.  A Proinflammatory Cytokine Inhibits P53 Tumor Suppressor Activity , 1999, The Journal of experimental medicine.

[35]  J. Bernhagen,et al.  MIF: a new cytokine link between rheumatoid arthritis and atherosclerosis , 2006, Nature Reviews Drug Discovery.

[36]  R. Mitchell.  Mechanisms and effectors of MIF-dependent promotion of tumourigenesis. , 2004, Cellular signalling.

[37]  S. Todo,et al.  An antibody for macrophage migration inhibitory factor suppresses tumour growth and inhibits tumour-associated angiogenesis. , 2000, Cytokine.